A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice

Infection and Immunity

Volumn 72, Issue 12, 2004, Pages 6945-6950

  Ferraz, Jose C ^a   Stavropoulos, Evangelos ^a   Yang, Min ^a   Coade, Steve ^a   Espitia, Clara ^b   Lowrie, Douglas B ^a   Colston, M Joseph ^a   Tascon, Ricardo E ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE PROLINE RICH ANTIGEN; BCG VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 70; MYCOBACTERIUM ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; DNA VECTOR; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PLASMID; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHAPERONINS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TUBERCULOSIS; VACCINES, DNA;

EID: 9244220647     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.12.6945-6950.2004     Document Type: Article

References (28)

1. Biet, F., L. Kremer, I. Wolowczuk, M. Delacre, and C. Locht. 2000. Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect. Immun. 70:6549-6557.
2. Dietrich, G., J. F. Viret, and J. Hess. 2003. Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments. Vaccine 21:667-670.
3. Dye, C., S. Scheele, P. Dolin, V. Pathania, and M. C. Raviglione. 1999. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. JAMA 282:677-686.
4. Espitia, C., R. Espinosa, R. Saavedra, R. Mancilla, F. Romain, A. Laqueyrerie, and C. Moreno. 1995. Antigenic and structural similarities between Mycobacterium tuberculosis 50- to 55-kilodalton and Mycobacterium bovis BCG 45- to 47-kilodalton antigens. Infect. Immun. 63:580-584.
5. Feng, C. G., U. Palendira, C. Demangel, J. M. Spratt, A. S. Malin, and W. J. Britton. 2001. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis. Infect. Immun. 69:4174-4176.
6. Ferraz, C. Ph.D. thesis. University College London, London, United Kingdom. (Submitted.)
7. Fine, P. E. M. 2000. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339-1345.
8. Goonetilleke, N. P., H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. Hill. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171:1602-1609.
9. Hart, P. D., and I. Sutherland. 1977. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Final report to the Medical Research Council. BMJ 2:293-295.
10. Hess, J., D. Miko, A. Catic, V. Lehmensiek, D. G. Russell, and S. H. Kaufmann. 1998. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. USA 95:5299-5304.
11. Horn, C., A. Namane, P. Pescher, M. Rivière, F. Romain, G. Puzo, O. Barzu, and G. Marchal. 1999. Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern. J. Biol. Chem. 274:32023-32030.
12. Horwitz, M. A., G. Harth, B. J. Dillon, and S. Maslesa-Galic. 2000. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97:13853-13858.
13. Jason, J., L. K. Archibald, O. C. Nwanyanwu, P. N. Kazembe, J. A. Chatt, E. Norton, H. Dobbie, and W. R. Jarvis. 2000. Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring. Infect. Immun. 70:6188-6195.
14. Kaufmann, S. H. 2001. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1:20-30.
15. + T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model. Infect. Immun. 71:1929-1937.
16. Lowrie, D. B., C. L. Silva, M. J. Colston, S. Ragno, and R. E. Tascon. 1997. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 15:834-838.
17. Murray, P. J., A. Aldovini, and R. A. Young. 1996. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad. Sci. USA 93:934-939.
18. Orme, I. M., D. N. McMurray, and J. T. Belisle. 2001. Tuberculosis vaccine development: recent progress. Trends Microbiol. 3:115-118.
19. Ponnighaus, J. M., P. E. M. Fine, J. A. Sterne, R. J. Wilson, E. Msosa, P. J. Gruer, P. A. Jenkins, S. B. Lucas, N. G. Liomba, and L. Bliss. 1992. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 339:636-639.
20. Pym, A. S., P. Brodin, L. Majlessi, R. Brosch, C. Demangel, A. Williams, K. E. Griffiths, G. Marchal, C. Leclerc, and S. T. Cole. 2003. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9:533-539.
21. Quintana, F. J., P. Carmi, F. Mor, and I. R. Cohen. 2002. Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60. J. Immunol. 169:3422-3428.
22. Ragno, S., M. J. Colston, D. B. Lowrie, V. R. Winrow, D. R. Blake, and R. E. Tascon. 1997. Protection of rats from adjuvant arthritis by immunization with naked DNA encoding for mycobacterial heat shock protein 65. Arthritis Rheum. 40:277-283.
23. Romain, F., A. Laqueyrerie, P. Militzer, P. Pescher, P. Chavarot, M. Lagranderie, G. Auregan, M. Gheorghiu, and G. Marchal. 1993. Identification of a Mycobacterium bovis BCG 45/47-kilodalton antigen complex, an immunodominant target for antibody response after immunization with living bacteria. Infect. Immun. 61:742-750.
24. Romain, F., C. Horn, P. Pescher, A. Namane, M. Riviere, G. Puzo, O. Barzu, and G. Marchal. 1999. Deglycosylation of the 45/47-kilodalton antigen complex of Mycobacterium tuberculosis decreases its capacity to elicit in vivo or in vitro cellular immune responses. Infect. Immun. 67:5567-5572.
25. Skinner, M. A., B. M. Buddle, D. N. Wedlock, D. Keen, G. W. de Lisle, R. E. Tascon, J. C. Ferraz, D. B. Lowrie, P. J. Cockle, H. M. Vordermeier, and R. G. Hewinson. 2003. A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis. Infect. Immun. 71:4901-4907.
26. Tascon, R. E., M. J. Colston, S. Ragno, E. Stavropoulos, D. Gregory, and D. B. Lowrie. 1996. Vaccination against tuberculosis by DNA injection. Nat. Med. 2:888-892.
27. Tascon, R. E., M. J. Colston, E. Stavropoulos, S. Ragno, D. Gregory, and D. B. Lowrie. 1997. Protection against tuberculosis by plasmid DNA, p. 181-185. In G. Gregoriadis, B. McCormack, and A. C. Allison (ed.), Vaccine design: the role of cytokine networks, vol. 293. Kluwer Academic Publishers, Hingham, Mass.
28. Xue, T., E. Stavropoulos, M. Yang, S. Ragno, H. M. Vordermeier, M. Chambers, R. G. Hewinson, D. B. Lowrie, M. J. Colston, and R. E. Tascon. Protective immune responses against M. tuberculosis infection conferred by RNA encoding MPT83 antigen. Infect. Immun., in press.